D.E. Shaw & Co
CLPT icon

D.E. Shaw & Co’s ClearPoint Neuro CLPT Stock Holding History

D.E. Shaw & Co’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-289,823
Closed -$3.46M – 4600
2025
Q2 		$3.46M Buy
289,823
+24,141
+9% +$304K ﹤0.01% 2312
2025
Q1 		$3.16M Sell
265,682
-22,727
-8% -$353K ﹤0.01% 2257
2024
Q4 		$4.44M Buy
288,409
+62,889
+28% +$815K ﹤0.01% 2076
2024
Q3 		$2.53M Buy
225,520
+146,489
+185% +$1.4M ﹤0.01% 2522
2024
Q2 		$426K Buy
79,031
+37,416
+90% +$217K ﹤0.01% 3725
2024
Q1 		$283K Buy
+41,615
New +$291K ﹤0.01% 3756
2023
Q3 		– Sell
-25,973
Closed -$188K – 4286
2023
Q2 		$188K Buy
+25,973
New +$221K ﹤0.01% 3754

Other funds holding CLPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Boone Capital Management Atlanta, Georgia $428M AUM 136.02% 1-Year Est. Return

D.E. Shaw & Co's CLPT Position: Q3 2025 in Review

D.E. Shaw & Co sold out of ClearPoint Neuro (CLPT) in Q3 2025, closing a stake of 289,823 shares — an estimated $3.46M sold.

D.E. Shaw & Co first reported a position in CLPT in Q2 2023 and held it in 7 quarters. The position peaked at $4.44M in Q4 2024. 107 funds tracked by Wall St. Rank hold CLPT as of Q3 2025.

  • D.E. Shaw & Co reported no remaining ClearPoint Neuro position as of Q3 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 289,823 ClearPoint Neuro shares in Q3 2025, an estimated $3.46M.
  • D.E. Shaw & Co first reported a position in ClearPoint Neuro in Q2 2023 and held it in 7 quarters.
  • D.E. Shaw & Co's ClearPoint Neuro position peaked at $4.44M in Q4 2024.
  • 107 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q3 2025.

Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.